Dana-Farber Accelerator Cancer Therapeutics Awardees
Following its Spring Therapeutics RFP, the Dana-Farber Accelerator awarded grants to several research teams developing innovative, early-stage therapeutic technologies. These projects include Understanding and Targeting Intrinsically Disordered Regions in Cancer from Cigall Kadoch, Chemical Manipulation of Tumor Creatine Energetics to Treat Colon Cancer from Ed Chouchani, and Membrane Protein Degraders for Immune Disease from Xin Zhou.
New Research Finds a Way to Make CAR T Cells Last Longer
Mohammad Rashidian’s CAR T Enhancer (CAR-E) therapeutic platform developed at Dana-Farber extends the activity of CAR T cells. Read more about the approach that enables CAR T cells to persist longer, increasing tumor clearance and development of memory cells for tumor growth control upon rechallenge.
Licensed Antiviral Peptide Platform Leads to New Therapeutic Agents and Positive Early Clinical Results
Dana-Farber and Red Queen Therapeutics are pioneering a novel stapled peptide technology, promising innovative antiviral therapies. Developed in Loren Walensky’s lab at Dana-Farber, this cutting-edge approach enhances peptide stability and derivatization, offering new hope in the fight against a variety of viruses.
Read more about the technology, clinical trial results, and development plans.
Amgen Partners of Choice Selects Two Dana-Farber Projects
The Amgen Partners of Choice (APoC) program is an initiative designed to foster strategic collaborations with leading academic institutions, biotech companies, and other organizations to accelerate the development of innovative therapies.
This year, two projects from Dana-Farber were selected for support from the APoC network. Learn more about Haeseong Park’s initiative for decoding biomarkers in gastric and esophageal cancer. The second project, led by Andrew Aguirre, MD and Brian Wolpin, focuses on advancing the understanding and treatment of pancreatic and colorectal cancer through the use of patient-derived organoid models. Learn more here.